{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-065564","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.214540+00:00","generated_at":"2026-05-24T04:17:01.891250+00:00","sec_items":["3.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biomea Fusion CEO Thomas Butler out; Board member Mick Hitchcock named interim CEO","bullets":["Thomas Butler terminated as CEO, resigned as director and Chairman effective March 25, 2025.","Michael J.M. Hitchcock (Mick) appointed interim CEO; Rainer Erdtmann named principal financial officer.","Audit Committee now has only two members due to Hitchcock's resignation; Nasdaq cure period until March 25, 2026.","Hitchcock receives $633,000 base salary, 50% target bonus, and options for 350,000 shares at $2.52/share.","Press release cites positive Phase II data for icovamenib as company pursues diabetes therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-065564","json":"https://secwatch.observer/filing/0001193125-25-065564.json","markdown":"https://secwatch.observer/filing/0001193125-25-065564.md","text":"https://secwatch.observer/filing/0001193125-25-065564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/d945354d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:17:01.891250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"057f321cc187def2cfed0df3b792f78128d84c18","claim":"Biomea Fusion, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)).","evidence_excerpt":"March 27, 2025, Biomea Fusion, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) due to the Company having only two members on its audit committee (the “Audit Committee”) of its Board of Directors of the Company (the “Board”) solely due to a vacancy resulting from Michael (Mick) J.M. Hitchcock, Ph.D.’s resignation from the Audit Committee in connection with his appointment as interim Chief Executive Officer of the Company effective March 25, 2025. The Company ha","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605(c)(2)(A), 5605(c)(4)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"14fd331325","claim":"Thomas Butler resigned as Chief Executive Officer at Biomea Fusion, Inc..","evidence_excerpt":"The employment of Thomas Butler as Chief Executive Officer of the Company ended on March 25, 2025 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"3eee4bff7d","claim":"Michael J. M. Hitchcock was appointed as interim Chief Executive Officer at Biomea Fusion, Inc..","evidence_excerpt":"Dr. Hitchcock, a member of the Board, was appointed as the Company’s interim Chief Executive Officer and principal executive officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"db7729a40e","claim":"Thomas Butler resigned as Director and Chairman of the Board at Biomea Fusion, Inc..","evidence_excerpt":"On the Effective Date, Mr. Butler resigned as a director and Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director and Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"fcb1a904c0","claim":"Rainer Erdtmann was appointed as Principal Financial Officer and Principal Accounting Officer at Biomea Fusion, Inc..","evidence_excerpt":"Rainer (Ramses) Erdtmann, the Company’s President, Chief Operating Officer and a member of the Board, was appointed as the Company’s principal financial officer and principal accounting officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525065564/0001193125-25-065564-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}